News

Quoin Pharmaceuticals seeks Breakthrough Medicine Designation for QRX003, aiming to provide the first treatment for Netherton Syndrome in Saudi Arabia.

Phase 1 cohort 4 data show soquelitinib demonstrated sustained clinical activity through 8 weeks, including in patients with prior systemic therapy exposure.

A WhatsApp-based pilot study revealed high patient knowledge and significant challenges in managing CSU among Spanish speakers.

Karen McGuire, PhD, discusses innovative TolaSure for treating epidermolysis bullosa simplex, focusing on disease modification rather than symptom management.

Public interest in GLP-1 weight loss medications surges, revealing concerns about aesthetic effects like "Ozempic face" and prompting new treatment strategies.

BOTOX Cosmetic's FDA approval for platysma bands revolutionizes non-surgical neck rejuvenation, offering dermatologists a new tool for effective patient care.

Explore the latest dermatology trends for 2026, including innovative therapies for psoriasis, atopic dermatitis, and hair loss advancements.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the commercial launch of cosibelimab-ipdl, dupilumab in pediatric AD, a phase 3 trial of lebrikizumab in nummular eczema, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

Psoriasis impacts physical and emotional health, with hidden burdens like trauma and IPV affecting quality of life and care access.

Renata Block, DMSc, MMS, PA-C, explores how AI could transform dermatology with insights from Dr. GPT on integration, equity, and the future of patient care.

Sun Pharma has launched cosibelimab-ipdl for advanced cutaneous squamous cell carcinoma, offering new hope for patients with limited treatment options.

Almirall initiates a pivotal phase 3 trial for lebrikizumab, targeting nummular eczema and aiming to enhance treatment options for this challenging condition.

Heap discusses promising phase 3 results for zasocitinib, an oral TYK2 inhibitor, showcasing its efficacy and safety in psoriasis therapy.

Researchers explore CO₂ laser therapy's effectiveness for refractory HHD, revealing its potential to restore skin health and reduce inflammation.

Discover how auricular acupuncture could enhance facial aesthetics, offering non-invasive rejuvenation with rapid results and minimal downtime for wrinkle reduction.

Topical roflumilast 0.3% cream shows promise in reducing lesions and symptoms of mild hidradenitis suppurativa (HS), offering a well-tolerated treatment option.

Explore the complexities of managing hidradenitis suppurativa (HS) through real-world case studies moderated by Afsaneh Alavi, MD.

Experts discuss real-world applications of JAK inhibitors for alopecia areata, emphasizing patient selection, psychosocial impacts, and personalized treatment strategies.

The National Psoriasis Foundation (NPF) redefines psoriasis severity, emphasizing disease impact over extent, enhancing treatment access, and aligning clinical practice with patient needs.

This review of the latest dermatologic studies includes insights on the "fear of overfilling," sexual adverse events from oral finasteride, post-laser, fibronectin-based skin care regimens, and more.

The RWEAL study uncovers real-world management of chronic hand eczema (CHE), highlighting treatment gaps and the need for standardized assessment in clinical practice.

Connect Biopharma reveals innovative data on rademikibart's mechanism of action, highlighting its potential impact on atopic dermatitis and future clinical priorities.

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.

Alpha Tau Medical advances Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC), offering a novel, localized treatment option with minimal toxicity.

Zasocitinib emerges as a highly selective and potent allosteric tyrosine kinase 2 (TYK2) inhibitor, showing promise for treating immune-mediated inflammatory diseases.